secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-08-13T01:36:55+00:00
Accession:  0001193125-26-347524
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo selects PTC and Lilly as winning bidders in $163.55M asset auction
--------------------------------------------------------------------------

- PTC to buy Fabry program (ST-920) for $111M cash + up to $100M milestones ($80M on accelerated approval, $20M on full approval).
- Lilly to buy capsid delivery, zinc finger, MINT platforms and prion program (ST-506) for $50M cash.
- Tools/equipment sold to various bidders for $2.55M; total cash consideration ~$163.55M.
- Sales subject to Bankruptcy Court approval; Lilly close expected ~Sept 4, 2026; PTC close after HSR review.
- Company continues to market ST-503, hemophilia A program, cell therapy and T-Reg assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/0001193125-26-347524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/d125617d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer